Vijay Gunuganti is an Oncology physician affiliated with Personalis. OpenAlex indexes 10 publications with 1,141 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
18707 Hardy Oak Blvd
Suite 320
San Antonio, TX 782584791
Telephone
210-545-6972Registry record last updated 28 Jan 2016.
Industry payments
58 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202579 payments$100,406openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202585 payments$99,810openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202528 payments$43,478openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.4%PD-1 inhibitor39.3%Nivolumab71%Pembrolizumab29%Part B, office-administered≥16 patientsMicrotubule Inhibitor14.1%Paclitaxel100%Part B, office-administered≥15 patients+ 12 more classes in this area
Metabolism & gastrointestinal
28.3%Other antiemetics24.2%Fosaprepitant100%Part B, office-administered≥32 patientsSerotonin-3 Receptor Antagonist3.4%Palonosetron hcl67%Granisetron hydrochloride31%Ondansetron Odt2%Ondansetron Hcl1%Part D + Part B≥45 patients+ 11 more classes in this area
Musculoskeletal
7.5%RANK Ligand Inhibitor7.2%Denosumab100%Part B, office-administered≥26 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥19 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”